Palatin Technologies (PTN) EBT Margin (2010 - 2026)
Palatin Technologies' (PTN) quarterly EBT Margin came in at 36.55% in Q1 2026, up 99.42% quarter-over-quarter from 6260.01% in Q4 2025.
Analysis
Palatin Technologies (PTN) EBT Margin (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported EBT Margin for 14 consecutive years, with 36.55% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin changed N/A year-over-year to 36.55%; the trailing twelve-month figure through Mar 2026 stood at 48.69% (up 661190.0% YoY), and the FY2024 full-year result was 662.26%, down 7071.0% from the prior year.
- EBT Margin climbed to 36.55% in Q1 2026 per PTN's latest filing, from 6260.01% in the prior quarter.
- Across five years, EBT Margin topped out at 52.97% in Q3 2025 and bottomed at 6260.01% in Q4 2025.
- Historically, EBT Margin has averaged 1411.1% across 5 years, with a median of 641.18% in 2023.
- The sharpest annual moves came in 2022 and 2024: EBT Margin soared 377444 bps in 2022, then slumped 179995 bps in 2024.
- Over 5 years, EBT Margin stood at 191.69% in 2022, then slumped by 101 bps to 385.62% in 2023, then tumbled by 511 bps to 2357.27% in 2024, then sank by 166 bps to 6260.01% in 2025, then soared by 99 bps to 36.55% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 36.55%, 6260.01%, and 52.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -36.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -36.55% |
| Dec 31, 2025 | -6,260.01% |
| Sep 30, 2025 | 52.97% |
| Jun 30, 2024 | -2,357.27% |
| Dec 31, 2023 | -385.62% |
| Sep 30, 2023 | -287.19% |
| Jun 30, 2023 | -557.31% |
| Mar 31, 2023 | -725.06% |
| Dec 31, 2022 | -191.69% |
| Sep 30, 2022 | -997.38% |
| Jun 30, 2022 | -1,656.54% |
| Mar 31, 2022 | -3,531.56% |
| Dec 31, 2021 | -2,696.49% |
| Sep 30, 2021 | -4,527.14% |
| Jun 30, 2021 | -3,458.45% |
| Mar 31, 2021 | -7,305.99% |
| Dec 31, 2020 | -5,639.27% |
| Sep 30, 2020 | -1,365.67% |
| Dec 31, 2019 | -25,443.96% |
| Sep 30, 2019 | -4,622.15% |